Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Equities research analysts at Wedbush cut their Q1 2025 earnings estimates for Neurocrine Biosciences in a note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.44 per share for the quarter, down from their prior forecast of $1.52. Wedbush has a “Outperform” rating and a $148.00 price target on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.93 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.75 EPS, Q3 2025 earnings at $1.85 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $7.23 EPS, FY2026 earnings at $9.89 EPS and FY2029 earnings at $21.23 EPS.
Several other analysts also recently weighed in on NBIX. Royal Bank of Canada reduced their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $165.40.
Neurocrine Biosciences Trading Down 0.4 %
Neurocrine Biosciences stock opened at $148.19 on Monday. The stock has a market cap of $15.00 billion, a P/E ratio of 39.73 and a beta of 0.33. The company has a fifty day simple moving average of $134.09 and a 200-day simple moving average of $131.27. Neurocrine Biosciences has a 12-month low of $110.95 and a 12-month high of $157.98.
Insider Activity
In other Neurocrine Biosciences news, CEO Kyle Gano sold 65,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now owns 135,392 shares of the company’s stock, valued at $19,157,968. This represents a 32.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the transaction, the insider now directly owns 2,507 shares of the company’s stock, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 68,694 shares of company stock valued at $9,676,730. Insiders own 4.30% of the company’s stock.
Hedge Funds Weigh In On Neurocrine Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in NBIX. Oakworth Capital Inc. acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at about $379,000. Choreo LLC raised its holdings in Neurocrine Biosciences by 44.3% in the 4th quarter. Choreo LLC now owns 3,765 shares of the company’s stock valued at $516,000 after acquiring an additional 1,156 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Neurocrine Biosciences by 21.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,358 shares of the company’s stock worth $2,251,000 after acquiring an additional 2,925 shares during the last quarter. Retirement Systems of Alabama boosted its holdings in shares of Neurocrine Biosciences by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 123,107 shares of the company’s stock worth $16,804,000 after acquiring an additional 446 shares during the period. Finally, abrdn plc increased its stake in shares of Neurocrine Biosciences by 14.8% during the fourth quarter. abrdn plc now owns 156,574 shares of the company’s stock worth $21,372,000 after purchasing an additional 20,150 shares during the period. 92.59% of the stock is owned by institutional investors.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Stories
- Five stocks we like better than Neurocrine Biosciences
- Trading Stocks: RSI and Why it’s Useful
- Sizing Up a New Opportunity for NVIDIA Investors
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- How to buy stock: A step-by-step guide for beginners
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.